All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
17 results for "Cancer" and "Gynecologic Cancers"
Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The objective is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus GEN-1 versus NACT alone
Protocol No
CELSION-201-17-201
Sub Category
Gynecologic Cancers
An Open Label, Non-Randomized Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma
To see combining three drugs, Bevacizumab, Atezolizumab and Rucaparib works well for previously treated recurrent Endometrial Cancer.
Protocol No
IIT-BRADLEY-ENDOBARR
Sub Category
Gynecologic Cancers
A Phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent Cervical Carcinoma
Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma
Protocol No
IOVANCE-C-145-04-CERVICAL
Sub Category
Gynecologic Cancers
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Radiation and Cisplatin with or without Triapine in Newly Diagnosed Cervical Cancer
Protocol No
NRG-GY006
Sub Category
Gynecologic Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Protocol No
SUTRO-STRO-002-GM1
Sub Category
Gynecologic Cancers
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Protocol No
BI-1381-REFMAL485
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab and RucAparib Combination Switch Maintenance following Front-Line Platinum-based Chemotherapy in Ovarian Cancer Patients
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)
Protocol No
GOG-3020-CLOVIS-CO-338-087
Sub Category
Gynecologic Cancers
Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®-TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer
A Trial of Tisotumab Vedotin in Cervical Cancer
Protocol No
GOG-3023-GENMAB-GCT1015-04
Sub Category
Gynecologic Cancers
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer
Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian
Protocol No
LEAP-DEK-DKKI-P204
Sub Category
Gynecologic Cancers
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
Protocol No
ASTRAZENECA-D0816L00003
Sub Category
Gynecologic Cancers
Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Protocol No
SWOG-S1316
Sub Category
Gastrointestinal Cancers
Prostate and Urologic Cancers
Gynecologic Cancers
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors ( Endometrial Cancer)
Protocol No
TESARO-4010-01-001
Sub Category
Gynecologic Cancers
A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Protocol No
NRG-GY007
Sub Category
Gynecologic Cancers
Phase II Open Label Nonrandomized Single Arm Trial of the Anti PD 1 Therapy Pembrolizumab in Combination with First Line Platinum Based Chemotherapy Followed by 12 Months Maintenance Pembrolizumab Monotherapy for Patients with Sub Optimally Cytoreduced Stage III/IV Epithelial Ovarian Cancer
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Protocol No
IIT-UYAR-MERCK-MISP52444
Sub Category
Gynecologic Cancers